Abstract: The invention relates to the use of alpha 1-antichymotrypsin (ACT) polypeptides according to SEQ ID No. 1 to SEQ ID No. 4 and/or nucleic acids encoding them, or an antibody or a fragment thereof directed against the polypeptide, or of a cell which is expressing the polypeptide or a nucleic acid encoding it, for diagnosis, treatment and/or prevention of diabetes-associated and/or arterial wounds which heal poorly and for identifying pharmacologically active substances which exert an influence on the expression or function, particularly the activity of ACT.
Type:
Grant
Filed:
April 30, 2002
Date of Patent:
August 14, 2007
Assignee:
Switch Biotech AG
Inventors:
Jörn-Peter Halle, Andreas Goppelt, Peter Hof
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
October 19, 2001
Date of Patent:
April 24, 2007
Assignee:
Genentech, Inc.
Inventors:
Luc Desnoyers, Ellen Filvaroff, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
October 16, 2001
Date of Patent:
March 27, 2007
Assignee:
Genentech, Inc.
Inventors:
Avi J. Ashkenazi, Kevin P. Baker, David Botstein, Luc Desnoyers, Dan L. Eaton, Napoleone Ferrara, Ellen Filvaroff, Sherman Fong, Wei-Qiang Gao, Hanspeter Gerber, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Kenneth J. Hillan, Ivar J. Kljavin, Sophia S. Kuo, Mary A. Napier, James Pan, Nicholas F. Paoni, Margaret Ann Roy, David L. Shelton, Timothy A. Stewart, Daniel Tumas, P. Mickey Williams, William I. Wood
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
October 16, 2001
Date of Patent:
March 27, 2007
Assignee:
Genentech, Inc.
Inventors:
Luc Desnoyers, Ellen Filvaroff, Wei-Qiang Gao, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
Abstract: The invention provides a novel reporter gene (mSEAP) capable of being expressed in a mammal for extended periods of time. Nucleic acids encoding the reporter gene, cells and vectors comprising the nucleic acids, and methods of using the reporter gene to identify expression vectors and screen for drug compounds in an animal are also disclosed.
Type:
Grant
Filed:
May 28, 2002
Date of Patent:
January 30, 2007
Assignee:
Aventis Pharma SA
Inventors:
Vincent Thuillier, Manping Wang, Cecile Orsini
Abstract: The present invention relates to isolated and/or purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase (DHS) nucleic acids and polypeptides. The present invention also relates to methods of modulating apoptosis using apoptosis-specific eIF-5A and DHS, and antisense oligonucleotides and expression vectors of apoptosis-specific eIF-5A and DHS useful in such methods.
Type:
Grant
Filed:
May 7, 2002
Date of Patent:
January 23, 2007
Assignee:
Senesco Technologies, Inc.
Inventors:
Catherine Taylor, Tzann-Wei Wang, Larry Petrov, John C. Carlson, Richard Narayansingh, Marianne Kaup, Dominic Cliche, John E. Thompson
Abstract: Materials and methods for reducing TGF-? production and promoting repair of liver damage in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of an anti-zvegf3 antibody in combination with a pharmaceutically acceptable delivery vehicle.
Abstract: Methods and compositions are provided for the creation and screening of non-human animal models having chronic inflammation. Immunocompromised host animals are injected with a population of immunocompetent effector cells, depleted of CD25+ T cells. The effector cells are tolerant of the host major histocompatibility antigens, but reactive to at least one antigen present in the host animal. The transferred cells are preferably stimulated and localized by administration of an immunostimulant at a local site. The animals are useful for a variety of screening assays and for investigation into disease causes and pathways. A variety of chronic inflammatory diseases may be studied with this model, including psoriasis, rheumatoid arthritis, diabetes, inflammatory bowel disease and multiple sclerosis.